[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Vaxcyte's Pipeline Timing Assumptions Haven't Been This Visible in Years

Vaxcyte Inc (PCVX) is scheduled to report second-quarter 2026 earnings on August 5, 2026, with the consensus estimate calling for a loss of $1.47 per share. The biotech company faces heightened scrutiny after missing estimates in each of the past four quarters, with losses deepening significantly beyond analyst expectations. Investors will be watching closely to see whether management can stem the tide of deteriorating results or if the pattern of widening misses continues.

Vaxcyte is a clinical-stage vaccine innovation company developing novel protein vaccines to prevent or treat bacterial infectious diseases. The company's lead candidates target pneumococcal disease and invasive Group A Streptococcus infections,...

Fundamentals

See More
  • Market Capitalization, $K 7,897,126
  • Shares Outstanding, K 144,398
  • Annual Sales, $ 0 K
  • Annual Income, $ -766,630 K
  • EBIT $ -1,089 M
  • EBITDA $ -1,078 M
  • 60-Month Beta 1.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.58

Options Overview Details

View History
  • Implied Volatility 55.60% (+0.54%)
  • Historical Volatility 45.82%
  • IV Percentile 40%
  • IV Rank 25.39%
  • IV High 90.62% on 11/04/25
  • IV Low 43.68% on 06/15/26
  • Expected Move (DTE 16) 5.10 (9.17%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 418
  • Volume Avg (30-Day) 234
  • Put/Call OI Ratio 2.87
  • Today's Open Interest 91,584
  • Open Int (30-Day) 92,370
  • Expected Range 50.49 to 60.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.47
  • Number of Estimates 1
  • High Estimate $-1.47
  • Low Estimate $-1.47
  • Prior Year $-1.22
  • Growth Rate Est. (year over year) -20.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.47 +5.58%
on 07/29/26
61.77 -10.31%
on 07/07/26
-2.99 (-5.12%)
since 07/02/26
3-Month
45.30 +22.30%
on 06/11/26
61.77 -10.31%
on 07/07/26
-0.24 (-0.43%)
since 05/05/26
52-Week
29.08 +90.51%
on 08/07/25
65.00 -14.77%
on 02/25/26
+21.67 (+64.25%)
since 08/05/25

Most Recent Stories

More News
Vaxcyte's Pipeline Timing Assumptions Haven't Been This Visible in Years

Barchart Research What to Expect from PCVX Earnings PCVX Generated August 4, 2026 Current Price $54.69 EPS Estimate $$-1.47 Consensus Rating Moderate Buy Average Move 5.17% Vaxcyte's Pipeline Timing Assumptions...

PCVX : 55.37 (+1.24%)
Vaxcyte to Participate in Upcoming Investor Conferences

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one...

PCVX : 55.37 (+1.24%)
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation...

PCVX : 55.37 (+1.24%)
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment Now Completed for OPUS-1, OPUS-2 and OPUS-3 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Topline Safety, Tolerability and...

PCVX : 55.37 (+1.24%)
Vaxcyte Approaches Its First Earnings Call Since Analysts Stopped Raising Targets

Barchart Research What to Expect from PCVX Earnings PCVX Generated May 5, 2026 Current Price $55.69 EPS Estimate $$-1.86 Consensus Rating Strong Buy Average Move 4.17% Vaxcyte Approaches Its First Earnings...

PCVX : 55.37 (+1.24%)
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...

PCVX : 55.37 (+1.24%)
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive...

PCVX : 55.37 (+1.24%)
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from...

PCVX : 55.37 (+1.24%)
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 55.37 (+1.24%)
STRO : 25.40 (-1.05%)
LZAGY : 69.4900 (+0.68%)
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety,...

PCVX : 55.37 (+1.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.

See More

Key Turning Points

3rd Resistance Point 56.80
2nd Resistance Point 55.94
1st Resistance Point 55.32
Last Price 55.37
1st Support Level 53.84
2nd Support Level 52.98
3rd Support Level 52.36

See More

52-Week High 65.00
Last Price 55.37
Fibonacci 61.8% 51.28
Fibonacci 50% 47.04
Fibonacci 38.2% 42.80
52-Week Low 29.08

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.